depression as a disease within the medical model and Sigmund Freud thought of it as a manifestation of psychodynamic processes. 1 In the 1950s and 60s with the development of anti-depressant medications, the monoamine hypothesis and serotonin hypothesis came to dominate psychiatric research. 2, 3 While being simple and elegant, the monoamine hypothesis ran into several difficulties, ranging from lack of universal response to therapeutic latency period. Experimental attempts to confirm the monoamine hypothesis faced difficult methodological problems, and produced no consistent results. 4, 5 Amidst this background, attention has slowly shifted towards the inflammatory (cytokine) hypothesis of depression in the last two decades. This hypothesis was first proposed by Smith in 1991 in the form of the 'macrophage theory of depression'. 6 To diagnose a case of Major Depressive Disorder (MDD), five of the following DSM-IV symptoms are required to be present for a minimum period of 2-weeks: (i) depressed mood; (ii) loss of interest or pleasure; (iii) significant weight or appetite alteration; (iv) insomnia or hypersomnia; (v) psychomotor agitation or retardation; (vi) fatigue and loss of energy; (vii) feelings of worthlessness or guilt; (viii) diminished ability to think or concentrate or indecisiveness; and (ix) suicidal ideation. 7 
MEtHodoLoGY
For the purpose of this review, a literature search for articles published during the last ten years was conducted using various combinations of key words ('depression', 'inflammation', 'cytokines', 'immune system', 'interleukins') utilizing the databases Google Scholar and PubMed. An outline of the most relevant aspects of the role of inflammatory processes in depression was created. Major papers, including other review articles, were identified in accordance with our outline. These articles were subsequently hand searched and reviewed individually for further references of significance.
Sickness Behavior and Evolutionary Background:
The body has a very organized strategy to combat infection, and this is manifested not just in fever and other physiological changes, but also in behavioral and affective alterations. The result is so-called sickness behavior, an adaptive set of behaviors induced by infection and inflammation consisting of lethargy, depression, loss of appetite, sleepiness and reduction in grooming. 8 The purpose of this is to conserve the energy resources of the sick individual and help fight back infection. Pro-inflammatory cytokines, produced by the activated innate immune system in response to specific Pathogen-Associated Molecular Patterns (PAMP), trigger sickness behavior. These cytokines include Interleukin (IL) 1, IL-6 and tumor necrosis factor α (TNF-α). 8 It has long been recognized that there are significant overlaps between sickness behavior and depression, such as anhedonia, decreased appetite, disturbed sleep, decreased activity and social withdrawal. 9 It may well be the case that depression is an evolutionary psychological byproduct of early mechanisms that promoted diversion of energy sources towards fighting the infection. 10 The dysregulation of glucocorticoid responses that has been observed in depression may have been of further advantage in this regard. 11 Before the modern human practices of hygiene and later development of antimicrobial agents, genes promoting sickness behavior would have been crucial in providing a survival advantage that would come at the cost of the risk of depression. It may be hypothesized that depressive mood disorder is an off-shoot of the genetic inflammatory machinery, which was otherwise of huge benefit in the pre-antibiotic era.
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A rEVIEW oF tHE EVIdEncE
1) Genetic Links between Inflammation and

Depression:
There have been several discoveries of associations between genes related to inflammation and depression. Jun TY et al reported that patients of Major Depressive Disorder had an increased frequency of the TNF2 (A) allele, suggesting that tumour necrosis factor-alpha gene polymorphism may play some role in the susceptibility for depression. 14 In another study by Wong ML et al, single nucleotide polymorphisms (SNPs) in two genes critical for T-cell function were found to be associated with predisposition for MDD. These two genes were responsible for antigen processing and differentiation. Furthermore, a significant combined allele dose-effect was revealed such that the likelihood of MDD increased with the number of alleles. 15 Revealing further genetic linkages, in a study by Yu YW et al it was observed that all patients of MDD who were homozygous for the -511T allele of the IL-1beta gene had less severity of depressive symptoms and more favorable Fluoxetine response compared to -511C carriers. 16 
2) Association of Depression with raised inflammatory markers:
The discovery that depression is associated with raised inflammatory markers was an early finding. A meta-analysis by Dowlati Y et al reported significantly higher concentrations of the proinflammatory cytokines TNF-α and IL-6 in patients of depression compared with control subjects. While individual studies have reported variable results both in favor and against, the meta-analysis strengthened the case in favor of depression's association with inflammatory response system. 17 This is supported by other studies such as a meta-analytic review reporting increased circulating IL-6 levels in depression 18 , and the WFSBP Task Force on Biological Markers study revealing a robust association with increase of soluble interleukin-2 receptor and interleukin-6 in serum, and impaired suppression of the dexamethasone suppression test. 
3) Association of Co-morbid Depression with Inflammatory Medical Illnesses:
As the role of inflammatory processes in the etiology of diseases such as diabetes 20 , cardiovascular events 21 and cancer 22 was being recognized, the high co-morbid rates of depression in these disease provided an indirect evidence for the inflammatory hypothesis of depression. 23 We have reports of high co-morbid depression in inflammatory diseases such as Rheumatoid Arthritis 24 , Fibromyalgia 25 , Inflammatory Bowel Disease 26 and Coronary artery disease. 27 Depression co-morbidity has also been reported in neurodegenerative disorders 28 such as Parkinson's and Alzheimer's diseases in which recent studies have also elaborated significant neuro-inflammation.
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4) Administration of Cytokines leads to Depression:
In many experimental studies carried out on animals, administration of cytokines has been demonstrated to produce depressive behavior in non-human primates such as monkeys. 32 Administration of TNF-α in mice has been shown to induce depressive behavior, which is attenuated by administration of anti-depressants. 33 In such studies, the relationship between the inflammatory marker and the response in the form of depressive behavior were followed up after the administration of the inflammatory mediators. In non-human primates, administration of a plethora of inflammatory cytokines was possible in different experimental settings. Such experiments cannot be conducted on human beings due to obvious ethical reasons; however, the clinical follow ups of hepatitis C patients undergoing treatment with interferon have provided significant data for humans. One study of HCV patients undergoing treatment reported a negative correlation of logtransformed CSF concentrations of IL-6 with logtransformed CSF 5-HIAA, a serotonin metabolite, which was found to be the strongest predictor of depressive symptoms in the study. 34 Another study investigating interferon (IFN) therapy in patients with hepatitis C (HCV) revealed that 33% of patients developed IFN-induced Major Depressive Disorder, 85% of which were responsive to antidepressant treatment. 35 Another study found significantly increased scores for depression (p <.001) and anger/hostility (p <.001) during IFN alpha therapy in the treatment group compared with the untreated reference group. 36 Furthermore, in patients with malignant melanoma, pretreatment with Paroxetine appears to be an effective strategy for minimizing depression induced by IFN alpha. 
5) Anti-Depressants have anti-inflammatory and neuro-protective properties:
The anti-inflammatory and neuro-protective role of anti-depressants is increasingly being recognized. Hwang J et al investigated the effects of tricyclic antidepressants using cultured brain cells as models. Their results showed that Clomipramine and Imipramine significantly decreased the production of nitric oxide and tumor necrosis factoralpha (TNF-a) in microglia and astrocyte cultures. Furthermore, the expression of pro-inflammatory cytokines was attenuated at mRNA levels. In the same study Clomipramine and Imipramine were shown to be neuroprotective as the drugs reduced microglia-mediated neuroblastoma cell death in the microglia/ neuron co-culture. 38 Similar results have also been demonstrated with studies involved Fluoxetine 39 as well as Paroxetine and Sertraline. 40 In a meta-analysis of human studies where cytokine levels were measured in patients of major depression before and after treatment with anti-depressants, it was demonstrated that IL-1β and possibly IL-6 levels were reduced, adding to the evidence regarding anti-inflammatory effects of anti-depressants.
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A rEVIEW oF PAtHoPHYSIoLoGIc MEcHAnISMS
The brain was previously considered to be an 'immune-privileged' organ but recent work has shown this conception to be mistaken. 42 ,43 The brain not only has inflammatory cells of its own (macrophages, microglia and dendritic cells) and possesses receptors for inflammatory mediators; peripheral inflammatory factors can also influence brain's functioning.
Cytokines and Blood-Brain Barrier:
There are a number of mechanisms by which peripheral cytokines can gain access to and/or influence central neural activity, as elaborated by Raison CL et al. 13 One pathway is via macrophagelike cells in the circumventricular organs and the choroid plexus (lying outside the blood-brain barrier), which detect and respond to circulating pathogen-associated molecular patterns by producing pro-inflammatory cytokines. These cytokines then cross the blood-brain barrier by volume diffusion. 44, 45 A second mechanism of cytokine entry into brain is via cytokine transporters at the blood-brain barrier 46 Perivascular macrophages and endothelial cells of brain venules have been shown to possess IL-1 receptors which respond by producing local prostaglandin E2, constituting a third pathway 47, 48 and lastly, activation of vagal afferent fibres has also been shown to communicate cytokine signals to various brain nuclei. 49 
Central Nervous System (CNS) Cytokine Network:
CNS has a network of immune cells (microglia) which produce cytokines, have cytokine receptors, amplify cytokine signals and influence neurotransmitter metabolism in brain areas, including those concerned with emotions and reward. 10, 13 Moreover, these inflammatory cytokines have significant stimulatory effects on brain CRH production and HPA axis hormones.
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Neurotransmitter Metabolism and Neurotoxicity:
Central to the cytokine effects on amino acid metabolism is the enzyme, Indoleamine 2,3Dioxy-genase (IDO). Cytokines lead to activation of IDO through multiple signaling pathways, including Nuclear Factor Kappa-light-chain-enhancer of activated B cells(NF-κB),Mitogen-Activated Protein Kinase (MAPK) and Signal Transducer and Activator of Transcription 5 (STAT5). 53 IDO breaks down Tryptophan, the precursor of Serotonin, into Kynurenine (KYN), resulting in a reduction in the level of Serotonin. 54 Reduction of Serotonin is associated with depression, as has long been known, but depression resulting from IDO activation and KYN production has additional Serotonin-independent effects as well. For instance, depressive behavior in mice has been demonstrated with administering KYN alone. 55 KYN is further converted into Quinolinic acid (QUIN) in microglia. 54 QUIN promotes glutamate release through activation of N-methyl-Daspartate (NMDA) receptors as well as producing oxidative stress, the combination of which leads to neurotoxicity. 56 
Diminished Neurotrophic Support and Decreased
Neurogenesis:
The CNS Cytokine network has also been shown to exert effects on neurotrophic support and neurogenesis, shedding new light on the pathophysiology of depression. Prominently, inflammatory cytokines hinder neuronal synaptic plasticity, decrease the levels of neurotrophic factors especially Brain Derived Neurotrophic Factor (BDNF), and reduce neurogenesis in the hippocampus. [57] [58] [59] Decreased levels of BDNF have also been reported to be a robust biological marker of major depression. 19 In support of this, Serotonin Specific Reuptake Inhibitors (SSRIs-the most commonly used antidepressants) have been shown to increase neurogenesis in the hippocampus 60 and potentiate the effects of BDNF. 61 In this context of decreased neurotrophic support, the neurotoxic effects of glutamate, as were noted previously, are further enhanced.
Hypothalamic-Pituitary-Adrenal (HPA) Axis and Glucocorticoid Resistance:
Cytokines have been shown to increase the levels of corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), and cortisol. These hormones have also been reported in studies to be elevated in patients of depression. 62, 63 The pathway for this appears to be impaired negative feedback regulation of HPA axis function and glucocorticoid resistance (determined by the dexamethasone suppression test). This is also, in part, related to reduced glucocorticoid receptor (GR) expression. 63, 64 Cytokine signaling molecules such as NF-κB, MAPK, and signal transducer and activator of transcription 5 (STAT5) have been demonstrated to inhibit GR. 65 As would be expected, antidepressants have been shown to restore the negative feedback control of HPA axis and increase GR expression.
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Psychological Stress Activates Pro-Inflammatory
Cytokines:
In cases of depression which occur in patients of various medical diseases, the source of inflammation is clear enough. One wonders what triggers the inflammation in patients of depression who are otherwise medically healthy. Recent work in this regard reveals that psychological stress can activate pro-inflammatory cytokines (such as IL-1 and TNF-α) and decrease anti-inflammatory cytokines (such as . This has been demonstrated in animals as well as humans, with both acute and chronic stress. [66] [67] [68] [69] [70] In addition, psychosocial stress can also activate NF-κB. 71 Psychosocial stress induced activation of NF-κB may also possibly occur via stimulation of sympathetic nervous system.
trEAtMEnt IMPLIcAtIonS
Screening Strategies:
The use of inflammatory biomarkers can potentially be used as a strategy to screen for patients with increased inflammatory activity who are less likely to respond to conventional anti-depressant therapy. Such patients may be more likely to benefit from inflammation targeted therapies.
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Possible Treatment with Anti-inflammatory agents:
Various studies have reported increased efficacy of treatment with the addition of anti-inflammatory agents to anti-depressants. Addition of Celecoxib to Sertraline 74 ,Fluoxetine 75 and Reboxetine 76 is of benefit with greater reduction of inflammatory markers and severity of depressive symptoms than either of the anti-depressant alone. Addition of Acetylsalicylic acid to Fluoxetine has also been shown to increase remission rates. 77 Usage of antagonists of TNF-α (Etanercept, Infliximab) without anti-depressants in the context of patients suffering from autoimmune disorders has also been shown to decrease the severity of depression. 78, 79 However, at the moment, no clinical recommendations can be made with regards to the use of anti-inflammatory agents in the treatment of depression, considering that current antiinflammatory drugs often have serious side-effects of their own. Celecoxib, for instance, is associated with adverse and potentially fatal cardiovascular thrombotic events. 80 Further research and development of possibly new anti-inflammatory agents specific to depression is required before any suggestions can be made regarding their clinical use.
New Target Areas for Medications:
The mechanism of how inflammation leads to depression provides many new target areas for researchers to explore in developing new medications. These target areas include cytokines and their signaling pathways (including NF-κB), CNS immune cells, such as microglia, NMDA Glutamate antagonists and neurotrophic factors.
Special Considerations for Pakistan:
Pakistan, like many 'third world' countries, suffers from high rates of chronic inflammatory illness. Two common ones include Tuberculosis 81 and Hepatitis C 82 . Given the high prevalence of these illnesses in Pakistan and the fact that both these illnesses would be expected to cause serious derangement of the immunomodulatory response, the review and recommendations above have a special significance for Pakistan. . Keeping in mind the evidence that has so far accumulated regarding the link between the inflammatory immune response and depression, increased vigilance and regular screening is required for early detection and treatment of depression in patients with chronic inflammatory illness (such as the above). Untreated depression in these patients can lead to noncompliance, partial or non-response to treatment and increased morbidity and mortality.
concLuSIon An impressive body of evidence has accumulated over the last two decades linking depression with inflammation, leading to the development of an inflammatory (cytokine) hypothesis of depression. Inflammatory response and mood regulation constitute a system of bi-directional communication such that inflammatory response leading to the formation of inflammatory cytokines can penetrate the CNS and influence behavior in the form of depression and sickness behavior, and mood regulatory system can potentially modify the immune system via the hypothalamus pituitary adrenal axis. Treatment implications include strategies to screen for patients with increased inflammatory activity who are less likely to respond to conventional anti-depressant therapy, possible treatment with anti-inflammatory agents, and the recognition of new target areas for researchers in developing new antidepressant medications. 
